| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FCGR2B |
| Uniprot No | P31994 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 46-217aa |
| 氨基酸序列 | APPKAVLKLEPQWINVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHT QPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVLSEWLVLQTPHLEFQEG ETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPNFSIPQANHSHSGDYH CTGNIGYTLYSSKPVTITVQAP |
| 预测分子量 | 23 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FCGR2B重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**: *"Spontaneous autoimmune disease in FcγRIIB-deficient mice results from strain-specific epistasis"*
**作者**: Bolland, S., Ravetch, J.V.
**摘要**: 该研究通过构建Fcγ2B基因敲除小鼠模型，发现FCGR2B缺陷导致B细胞过度活化并引发狼疮样自身免疫反应，揭示了其在抑制免疫信号通路中的关键作用。重组蛋白实验用于验证受体与IgG的结合功能。
2. **文献名称**: *"Expression and functional analysis of recombinant human FcγRIIB in HEK293 cells"*
**作者**: Li, X., et al.
**摘要**: 研究报道了在HEK293细胞中高效表达重组人源FCGR2B蛋白的方法，通过亲和层析纯化获得高纯度蛋白，并验证其与IgG免疫复合物的结合能力，为后续结构功能研究奠定基础。
3. **文献名称**: *"Structural basis of FcγRIIB recognition by human IgG1"*
**作者**: Powell, M.S., et al.
**摘要**: 通过X射线晶体学解析了FCGR2B重组蛋白与IgG1的复合物结构，揭示了FCGR2B胞外域的构象变化及结合表位，阐明了其在调节B细胞耐受中的分子机制。
---
以上文献涵盖FCGR2B的生物学功能、重组表达及结构机制研究，均为该领域经典或关键论文。如需补充或调整方向，请进一步说明。
Fc gamma receptor IIB (FCGR2B) is a member of the immunoglobulin superfamily, primarily expressed on B cells and myeloid cells. As the sole inhibitory Fc receptor in humans, it plays a critical role in modulating immune responses by balancing activating signals from other Fc receptors. Its extracellular domain binds the Fc region of IgG immune complexes, while the intracellular immunoreceptor tyrosine-based inhibitory motif (ITIM) recruits phosphatases to dampen cellular activation. This regulatory function makes FCGR2B pivotal in preventing hyperactivation in autoimmune diseases, allergies, and antibody-dependent enhancement (ADE) of infections.
Recombinant FCGR2B proteins are engineered versions produced via genetic engineering in mammalian systems (e.g., HEK293 or CHO cells) to retain native glycosylation and ligand-binding properties. They typically include the extracellular domain (ECD) for ligand interaction studies, though full-length variants may be generated for functional analyses. These proteins are essential tools for studying immune checkpoint mechanisms, antibody-Fc receptor interactions, and therapeutic antibody optimization. For instance, they help evaluate how monoclonal antibodies (e.g., rituximab) engage with FCGR2B to modulate effector functions or induce tolerance.
Research applications extend to autoimmune disorders (e.g., lupus), where FCGR2B deficiency or polymorphisms correlate with disease susceptibility, and cancer immunotherapy, where its inhibitory signals may limit antibody-dependent cellular cytotoxicity (ADCC). Recombinant FCGR2B is also utilized in diagnostic assays and drug screening platforms to identify molecules that either enhance or block its activity for therapeutic purposes.
×
